Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
218.06
-7.15 (-3.17%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biogen Idec
< Previous
1
2
...
23
24
25
26
27
28
29
30
31
...
37
38
Next >
10 Biggest Price Target Changes For Monday
December 20, 2021
JP Morgan raised the price target on Public Storage (NYSE:
Via
Benzinga
EMA's Committee Gives Thumbs Down To Biogen's Controversial Alzheimer's Drug, As Expected
December 17, 2021
The European Medicines Agency has recommended the European Commission to reject Biogen Inc's (NASDAQ: BIIB) Aduhelm, an expected blow to its hopes of finding a...
Via
Benzinga
The Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx
December 17, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Merck Announces Publication Of Positive Data From Late-Stage Study Of Oral...
Via
Benzinga
Biogen Outlines Aduhelm's Confirmatory Trial Plans, Data Expected In 2026
December 16, 2021
Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) are looking to get initial data from the FDA-mandated confirmatory trial for its Alzheimer’s...
Via
Benzinga
Where Biogen Stands With Analysts
December 06, 2021
Analysts have provided the following ratings for Biogen (NASDAQ:BIIB) withi...
Via
Benzinga
Where Biogen Stands With Analysts
November 19, 2021
Biogen (NASDAQ:BIIB) has observed the following analyst ratings within the ...
Via
Benzinga
The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street
December 16, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug...
Via
Benzinga
Eli Lilly Pops On Boosted 2021 Outlook As Covid Brings In $2.1 Billion
December 15, 2021
The U.S. government recently signed a deal for Lilly's Covid antibodies.
Via
Investor's Business Daily
More Specificity is What the Doctor Ordered
December 14, 2021
Photo by Steven HWG on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner...
Via
Benzinga
Amid Shaky Launch Of Aduhelm, Biogen Mulls Substantial Layoffs: STAT News Report
December 10, 2021
Between slow sales, safety concerns, and possible European rejection for Alzheimer's disease drug Aduhelm, Biogen Inc (NASDAQ: BIIB) is planning large-scale layoffs...
Via
Benzinga
Omicron Surge
December 09, 2021
The seemingly good level of joblessness at a mere 184,000 turns out to be less wonderful than it appears, at the lowest since 1969.
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021
December 09, 2021
Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ:
Via
Benzinga
The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom
December 08, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus EyePoint Announces Commercialization Agreement For Dexycu To Treat Post-...
Via
Benzinga
Topics
Intellectual Property
Lawsuit
Exposures
Financial
Intellectual Property
Legal
Early Clinical Data Suggest This New Lotion Could Offer Best-In-Class Eczema Treatment and Infection Prevention, According to Hoth Therapeutics
December 07, 2021
Image Provided By Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of...
Via
Benzinga
Should You Blame Biogen for Medicare Part B Premium Hikes?
December 03, 2021
Yes -- at least partially.
Via
The Motley Fool
Sage Therapeutics - Biogen Share One Year Zuranolone 50mg Data In Depression Patients
December 01, 2021
Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have announced 12-month data for the cohort of patients (n=199) who received zuranolone...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2021
December 06, 2021
Upgrades According to TD Securities, the prior rating for MAG Silver Corp (AMEX:
Via
Benzinga
The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment; Regulatory Setbacks For CTI Biopharma, BioXcel; Favorable Ruling For Viatris In Tecfidera Patent Case
December 01, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Adcom Backing For Oral COVID-19 Antiviral Medication Molnupiravir...
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Biogen Loses Bid To Revive Tecfidera Drug Patent: Bloomberg
November 30, 2021
Biogen Inc (NASDAQ: BIIB) lost its appeals court bid to revive a key patent on the blockbuster multiple sclerosis drug Tecfidera, reports Bloomberg. In a related ruling...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Could Roche Put a Crinkle in Biogen's Alzheimer's Drug Launch?
November 28, 2021
The Swiss pharma needs to get its drug approved first.
Via
The Motley Fool
Exposures
Product Safety
2 Moonshot Biotechs with 10x Potential
November 22, 2021
This strategy identified LGVN stock a month ago, and now its price has skyrocketed. Here are two more biotechs that could do the same.
Via
InvestorPlace
The Week Ahead In Biotech (Nov. 21-Nov. 27): FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
November 21, 2021
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting...
Via
Talk Markets
Exposures
Product Safety
The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
November 21, 2021
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the...
Via
Benzinga
Exposures
Product Safety
Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar?
November 18, 2021
Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation...
Via
Benzinga
European Regulator Votes Down Biogen's Alzheimer's Drug
November 17, 2021
Following an oral explanation held at the November meeting of the EMA's human medicines committee, Biogen Inc (NASDAQ: BIIB) received "a negative trend vote...
Via
Benzinga
Biogen Stock Skids After Alzheimer's Drug Aduhelm Faces A Setback In Europe
November 17, 2021
The committee voted against recommending Aduhelm approval.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
November 19, 2021
Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE:
Via
Benzinga
Jim Cramer Likes This Stock Over Cassava Sciences And Biogen
November 17, 2021
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Cassava Sciences, Inc. (NASDAQ:
Via
Benzinga
Could Eli Lilly Leapfrog Biogen in This Market?
November 17, 2021
Biogen is benefiting from a first-mover advantage, but the race is far from over.
Via
The Motley Fool
Europe OKs Biogen's Vumerity For Multiple Sclerosis
November 16, 2021
The European Commission has approved Biogen Inc's (NASDAQ: BIIB) Vumerity (diroximel fumarate) to treat adults with relapsing-remitting multiple sclerosis (MS...
Via
Benzinga
< Previous
1
2
...
23
24
25
26
27
28
29
30
31
...
37
38
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.